Use of Bedinvetmab (Librela) for Canine Osteoarthritis in France, Germany, Italy, Spain, and the UK: Quantitative Analysis of Veterinarian Satisfaction and Real-World Treatment Patterns.

Bedinvetmab (Librela) represents a new class of canine osteoarthritis pain therapy. The aim of this study was to understand patient selection, usage behaviours, and satisfaction amongst veterinarians using bedinvetmab. Overall, 1932 patient record forms (PRF) were collected from 375 veterinarians across five countries in Europe.

Bovine somatotropin dose titration in lactating dairy ewes. 3. Treatment interval.

Seventy-four lactating dairy ewes were injected with recombinant bovine somatotropin (bST; sometribove) in a sustained-release formulation. Ewes received 0, 80, 160, or 240 mg of bST/14 d at the end of 2, 4, and 6 wk postlambing, after which injections were withheld for a 28-d period. Response of milk production to bST presented a positive linear contrast and a negative quadratic contrast.

The effect of bovine somatotropin and diet on somatotropin binding sites in hepatic tissue of lactating dairy cows.

In the lactating cow, galactopoiesis is stimulated by treatment with recombinant bovine somatotropin (bST) and by an improved plane of nutrition. The present study determined the interaction between these variables and examined whether a positive galactopoietic effect was accompanied by a change in hepatic binding sites for bST. Lactating dairy cows received one of three diets with increasing nutrient density; diet 1, 150 g/kg of dry matter (DM) of crude protein (CP) and 10.

Use of bovine somatotropin in the tropics: the effect of sometribove on milk production in western, eastern, and southern Africa.

Seven field studies conducted in western, eastern, and southern Africa to determine the effect of a prolonged-release formulation of bovine somatotropin (bST) administered at 14-d intervals on milk production of indigenous, crossbred, and purebred cows are described. Studies in Gambia showed that 334 mg of a prolonged-release formulation of bST increased milk production of N'Dama cattle by 205 ml/d, which represented a 22% increase in milk production, and increased the body weight gain of calves. In small dairy units in Zimbabwe, 500 mg of a prolonged-release formulation of bST increased milk production of crossbreds from 8.

Pituitary response to thyrotropin, corticotropin, and gonadotropin-releasing hormones in lactating cows treated with sometribove for a fourth consecutive lactation.

The effect of chronic treatment with recombinant methionyl bovine somatotropin (USAN, sometribove) on anterior pituitary secretions and its target organs was investigated in six control and six sometribove-treated British Friesian cows. Cows averaged 112 and 119 d postpartum in their fourth lactation of treatment and, except for one control, had active corpora lutea. During each lactation, treated cows received sometribove injections (500 mg) every 2 wk (injection cycle) starting 60 +/- 3 d postpartum.

Bovine somatotropin dose titration in lactating dairy ewes. 1. Milk yield and milk composition.

Seventy-four lactating dairy ewes were injected with recombinant bST (sometribove) in a sustained-release formulation. Ewes received 0, 80, 160, or 240 mg of bST every 14 d from wk 3 to 8 of lactation (part 1) and 0, 80, or 160 mg of bST every 14 d from wk 11 to 23 of lactation (part 2). Sometribove increased milk yield over that of the controls for all treatment groups.

Clinical mastitis in cows treated with sometribove (recombinant bovine somatotropin) and its relationship to milk yield.

Effect of sometribove (methionyl bovine somatotropin) on mastitis in 15 full lactation trials (914 cows) in Europe and the US and 70 short-term studies (2697 cows) in eight countries was investigated. In full lactation studies, sometribove (500 mg/2 wk) was given for 252 d, commencing 60 d postpartum. Although herds varied considerably, incidence of clinical mastitis within a herd was similar for cows receiving control and sometribove treatments.

Single-strand conformation polymorphism (SSCP) analysis of the COL3A1 gene detects a mutation that results in the substitution of glycine 1009 to valine and causes severe Ehlers-Danlos syndrome type IV.

A single base mismatch was detected by single-strand conformation polymorphism (SSCP) of the collagen type III gene in a patient with Ehlers-Danlos syndrome type IV. The patient's fibroblasts secreted both normal and slowly migrating type III procollagen molecules. Two-dimensional CNBr peptide mapping suggested that the defect was localised in the CB9 peptide or the C-propeptide region of the alpha 1 (III)-chain.

Long-term effects of sometribove in lactating cows during a fourth consecutive lactation of treatment: insulin and somatotropin responses to glucose infusion.

The effect of sometribove (USAN, methionyl bST) on the endocrine pancreas and blood bST concentrations was investigated in 6 control and 6 treated Friesian cows, averaging 111 and 118 d postpartum in their fourth lactation of treatment. Each lactation the treated cows received sometribove injections (500 mg) every 2 wk (injection cycle) starting 60 +/- 3 d postpartum, increasing milk yield 3.3, 5.

[Echographically controlled ventricle punctures].

Ventricular taps are performed either for diagnostic or for therapeutic purposes. They are not free of risks. A new technique is presented, in which the placement of the needle is echographically monitored.